BioCentury
DATA GRAPHICS | Deals

Data Bytes: 2020’s top 10 gene and cell therapy deals to date

Eight of the 10 largest cell and gene therapy deals this year have crossed the $1 billion mark

August 6, 2020 12:45 AM UTC

The cell and gene therapy field continues to be a driver of high-value deals frequently breaking the billion dollar mark. Eight of the 10 largest cell and gene therapy deals so far this year have met that description. Combined, the maximum value of the 10 deals is nearly $18 billion.

Cancer stands out as the top therapeutic area among the deals, with this year’s largest cell and gene therapy partnership between Fate Therapeutics Inc. (NASDAQ:FATE) and the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) covering off-the-shelf CAR NK and CAR T therapies against up to four tumor antigens (see “Janssen Takes Another Shot at Off-the-shelf CAR Ts”)...